Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 2058-2063, 1997;
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (87)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clemens, J. D.
Right arrow Articles by Eyre, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clemens, J. D.
Right arrow Articles by Eyre, D. R.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 1997;43:2058-2063.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption

J. Daniel Clemens1,a, Michael V. Herrick1, Frederick R. Singer2 and David R. Eyre3

1 Ostex International, Inc., 2203 Airport Way South, Suite 400, Seattle, WA 98134.

2 John Wayne Cancer Institute, Santa Monica, CA.

3 Orthopedic Research Labs, University of Washington, Seattle, WA.
a Author for correspondence, Fax 206-292-8625; e-mail dclemens{at}ostex.com


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Previous studies have shown that immunoassay of urinary NTx (cross-linked N-telopeptides of type I collagen) provides a responsive index of human bone resorption. Here we report by a sensitive immunoassay that NTx is present in serum and is suppressed appropriately in patients with Paget disease of bone by bisphosphonate antiresorptive therapy. The monoclonal antibody (1H11) developed against urinary NTx was applied in a sensitive chemiluminescence format. Results for human serum and urine showed parallel inhibition curves. The NTx concentrations in paired serum and urine samples from individual patients correlated well when urinary concentrations were normalized to creatinine concentrations (in premenopausal and postmenopausal women and Paget disease patients, r = 0.90, n = 60). The percentage of NTx suppression from baseline values for Paget disease patients on bisphosphonate therapy was similar for serum and urine. Blood samples drawn from bone marrow at the site of Pagetic lesions in three patients with active disease had as much as 10-fold higher concentrations of NTx than did peripheral blood samples drawn at the same time. The latter finding is consistent with other evidence showing that immunoreactive NTx originates directly during the proteolytic cleavage of bone collagen by osteoclasts rather than, e.g., by degradative processes occurring later in the liver and kidney.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Immunoassays for biochemical markers of bone resorption are emerging that appear to be sufficiently specific and convenient for clinical use (1)(2)(3)(4)(5)(6). There is a need for such tests because, as the impact of osteoporosis on the aging population increases, the choice of therapies widens and better tools are sought to aid in risk prediction and prevention of osteoporosis. Recently, several new molecular markers and convenient immunoassays have been introduced, some of which may have the specificity to detect the relatively subtle changes in bone turnover rate that occur, e.g., in postmenopausal osteoporosis.

Collagen metabolites in urine are thus far the best resorption markers (7)(8)(9)(10). The focus has narrowed to collagen cross-linking amino acids and peptides that contain them. Pyridinolines (hydroxylysyl pyridinoline and lysyl pyridinoline) in total or as the free fraction in urine have been measured by HPLC or immunoassay (11)(12)(13). Type I collagen telopeptide sequences that contain these cross-linking residues are also proving to be reliable and, as shown in comparative studies, are more responsive and osteoclast-specific markers of bone resorption than are the free cross-links themselves (14)(15)(16)(17)(18)(19)(20).

A resorption assay that measures cross-linked N-telopeptides of type I collagen (NTx)1 in urine was described (21). A commercial ELISA version is available (Osteomark®; Ostex International) that can measure the excretion of NTx in spot (untimed) urines or 24-h collections. Results are normalized to creatinine concentration. A reliable immunoassay to measure NTx in serum could avoid the added variability of having to normalize urine values to creatinine and might aid in understanding the metabolism and kidney clearance of the NTx peptides. Therefore, we set out to determine whether the same analyte could be measured in serum with a sensitive research-grade chemiluminescence immunoassay. We demonstrate here the ability to measure immunoreactive NTx in human serum and present findings to show that this analyte responds appropriately in monitoring the clinical response to antiresorptive therapies in Paget disease patients.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
clinical samples
Patients were selected with mild to severe Paget disease. Severely affected patients were identified on the basis of having particularly high serum total alkaline phosphatase activities (>1000 U/L). All serum, marrow blood, and urine specimens were collected under investigational review board approval from the clinical sites. Specimens were stored frozen (-20 °C) before analysis.

serum immunoassay procedure
A chemiluminescence immunoassay in competitive inhibition format was developed to use the mouse monoclonal antibody, mAb 1H11, and the NTx antigen prepared from human bone by bacterial collagenase digestion, essentially as described previously (21). MAb 1H11 was purified and conjugated to horseradish peroxidase (HRP) by a modification of the method described by Nakane and Kawaoi (22). Sterile polystyrene tubes (12 x 75 mm) were coated with the NTx antigen by passive adsorption at 0.5 nmol BCE/L2 in 100 mmol/L phosphate buffer, pH 8.0. For assay use, the labeled antibody, mAb 1H11–HRP, was diluted to 5 µg/L in 2 mmol/L phosphate, 2.5 mL/L Tween-20, 10 mmol/L 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate buffer. Test specimens and assay calibrators were diluted 1:22.5 in 2 mmol/L phosphate buffer, pH 8.0, and then combined in an equivolume (1:1) ratio with diluted mAb 1H11–HRP in coated tubes. Dilution was required to minimize an interference by serum protein in the assay. At all dilutions of test specimens and calibrators, assays were run in duplicate. Mean values were used for the final results. The samples were incubated for 1 h in a refrigerator at 4 °C to allow competition for antibody binding sites. The contents of each tube were then aspirated and the tubes were washed twice with deionized water. Luminescence development buffer—0.06 mmol/L luminol (Sigma Chemical Co.), 0.12 mmol/L iodophenol (Aldrich Chemical Co.), and 0.6 g/L hydrogen peroxide in 100 mmol/L phosphate, pH 8.0—was then added to each tube. The light signal was quantified immediately with a Berthold Lumat LB 9501 luminometer purchased from EG&G Wallac (Gaithersburg, MD). Sample measurements were read from the calibration curve with use of a 4-parameter logistic curve-fitting program. The calibration curve measurement range was 0–40 nmol BCE/L. Specimens giving results greater than the upper limit of the calibration curve were diluted further in the 2 mmol/L phosphate buffer described above. Final immunoassay results are reported in nanomoles of BCE per liter.

assay performance
Intraassay variability was calculated for duplicate analyses of seven serum specimens run in three separate assays. Interassay variability was calculated from the means from each of the three assays.

The detection limit was determined in each of 10 assays as the antigen concentration at a point on the curve 2 SD above the mean signal for the zero calibrator. The mean detection limit from the 10 assays was taken as the overall lower limit of detection of the method.

Antigen recovery was determined for four serum and four plasma (heparin-treated) specimens to which had been added the antigen (179 nmol BCE/L) used for assay calibration. We used a Paget disease serum to check linearity on dilution (1:2, 1:4, 1:8) in the 2 mmol/L phosphate buffer in three separate assays.

urine ntx determinations
Urinary NTx was quantified with the Osteomark immunoassay kit. Results are reported normalized to urinary creatinine as measured by the Jaffe method (23) (with a reagent kit purchased from Sigma) and expressed as nmol BCE/mmol creatinine.

The Osteomark immunoassay imprecision (CV) was <8%, and the lower limit of detection was 20 nmol BCE/L. Urinary creatinine assay imprecision was <4%.

collection of marrow blood samples from pagetic lesions
Informed consent was obtained from three patients with Paget disease who had radiological evidence of the disease in at least one iliac crest and serum alkaline phosphatase activity at least twice the upper reference limit. Bone marrow aspiration was carried out from the posterior superior iliac crests exhibiting Paget disease under xylocaine local anesthesia. The marrow was aspirated into a syringe containing a known volume of {alpha} Minimum Essential Medium that included heparin 1000 IU/mL and fetal calf serum 50 mL/L. After centrifugation, the plasma was stored frozen (-70 °C) until analysis.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
assay performance
The reproducibility of the chemiluminescence immunoassay is presented in Table 1 . The mean intraassay and interassay CVs were 7.7% and 13.4%, respectively. The lower limit of detection of the method was 0.84 nmol BCE/L (range 0.05–2.1 determined over 10 assays). Antigen recovery was 87% (range 77–94%) in four serum specimens and 98% (range 89–121%) in four plasma specimens. Mean dilutional recoveries for a Paget disease serum sample were 113%, 99%, and 108% at 1:2, 1:4, and 1:8 dilutions, respectively.


View this table:
[in this window]
[in a new window]
  		Table 1. Reproducibility of the chemiluminescence immunoassay for NTx in human serum.

Parallel inhibition curves for serum and urine (not shown) and acceptable recoveries on addition to serum specimens of the antigen used to calibrate the urine assay (Osteomark) demonstrate that mAb 1H11 recognizes essentially the same epitope in serum and urine. Moreover, fractionation of NTx species from Paget disease serum by molecular sieve and reversed-phase chromatography indicated immunoreactivity in the same low-molecular-mass range with chromatographic properties similar to those of the NTx peptides from urine (data not shown). This is consistent with the conclusion that the epitope recognized by mAb 1H11 requires proteolysis of the cross-linked {alpha}2(I) N-telopeptide domain of type I collagen to an 8 amino acid sequence (21)(29).

comparative results for premenopausal, postmenopausal, and paget disease patients
To test whether the serum NTx marker was clinically discriminatory, we assayed matched collections of urine and serum from different Paget patients who varied in disease severity (according to their degree of increase of bone turnover markers). Postmenopausal subjects with increased bone resorption, as judged by their urinary NTx values, were compared with a group of premenopausal women who exhibited normal rates of bone resorption. Serum and urine NTx results were compared from 32 premenopausal women, 21 postmenopausal women, and 7 patients with Paget disease of bone. Table 2 compares the mean values for serum and urine for these subject groups. Mean values were higher in the Paget disease patients than in the premenopausal group (4.5-fold greater in serum, 5.9-fold greater in urine), and also in the postmenopausal group compared with the premenopausal group (1.6-fold greater in serum, 2.0-fold greater in urine). The correlation between paired serum and urine samples for the entire population (n = 60) was r = 0.90 (Fig. 1 ).


View this table:
[in this window]
[in a new window]
  		Table 2. Comparison of NTx assay results for paired serum and urine samples from different subject groups (mean ± SD).



View larger version (20K):
[in this window]
[in a new window]
  		Figure 1. Correlation of serum and urine NTx measurements on paired samples from individual subjects.

The subject group (n = 60) included premenopausal (n = 32) and postmenopausal (n = 21) women and Paget disease patients (n = 7).

The response to antiresorptive therapy was assessed in three additional patients with Paget disease of bone, who were monitored during an 8-week course of oral residronate (30 mg daily) and for 4 months afterwards. Suppression in bone resorption was seen in both serum and urinary NTx values (Fig 2 ). The paired serum and urine values for each patient were highly correlated (r = 0.90, 0.94, and 0.97).



View larger version (26K):
[in this window]
[in a new window]
  		Figure 2. Monitoring bone resorption by serum ({blacksquare}) and urine ({blacktriangleup}) NTx measurements in individual Paget disease patients on bisphosphonate therapy.

Three patients with severe disease were given oral residronate (30 mg/day) for 8 weeks and followed from baseline through therapy to 17 weeks posttherapy.

ntx concentrations in marrow blood vs peripheral blood
Marrow blood drawn from the site of a Pagetic lesion and peripheral blood were collected simultaneously from three more Paget patients. The assay results for serum from these samples are compared in Table 3 . The {alpha} Minimum Essential Medium used to collect and dilute the marrow was shown to give no signal in the NTx immunoassay (<0.84 nmol BCE/L). For all three patients, NTx was much more concentrated in the marrow blood than in peripheral blood. This is consistent with NTx being generated as a direct product of the resorptive action of osteoclasts, which are abundant at the site of a Pagetic lesion. The actual values for individual patients will clearly depend on how closely the marrow blood was drawn from the site of involvement and, for the peripheral blood sample, the degree to which multiple bony lesions contributed systemically.


View this table:
[in this window]
[in a new window]
  		Table 3. Comparative NTx values for marrow blood vs peripheral blood from three Paget disease patients.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
The results show that the immunoreactive peptide analyte, NTx, originally identified in urine as a product of osteoclastic bone resorption, can also be measured in human serum. A sensitive immunoassay can quantify the concentrations in serum reliably. Premenopausal, postmenopausal, and Paget disease patients can be distinguished well by serum analysis and by urine analysis, although the data presented here show a somewhat greater discriminatory power for urine NTx than for serum NTx. A growing body of clinical studies has shown that urinary NTx provides a sensitive marker of human bone resorption (4)(6)(14)(15)(16)(17)(18)(19)(24)(25)(26)(27)(28). Its specificity is based on originating solely from type I collagen, being particularly enriched as a cross-linking structure in bone type I collagen (29) and being produced directly as a proteolytic neoepitope by osteoclast activity during bone resorption (30). Analysis of urine specimens has certain advantages, including ease of collection and reduced biohazard precautions for clinical laboratory personnel than with bloodbased specimens. However, a serum marker with similar specificity would have other advantages, e.g., avoiding the potential added variability with urine from having to normalize results to creatinine or in collecting 24-h specimens, and greater availability of blood specimens, which are often drawn for other measurements anyway. Finally, in renal failure patients, who are at risk of metabolic bone disease, urine may not be an option and serum could be informative.

The finding of a high NTx concentration in marrow blood taken from a bony lesion site in Paget disease, compared with peripheral blood, supports the concept that NTx is a proteolytic neoepitope generated by osteoclasts as they resorb bone. A study of mouse osteoclasts cultured on human bone or dentin also showed the release of NTx into the culture medium (30). The yield of immunoreactive NTx was also quantitative, as judged by the amount of resorbed collagen in the medium and its theoretical NTx content. This latter study also showed that the cultured osteoclasts degraded the resorbed bone collagen to peptide-bound pyridinolines but not to free pyridinolines.

The serum concentration range of NTx compared with 24-h urine values for normal subjects indicates a plasma clearance exceeding 28 mL/min, assuming zero protein binding and no renal metabolism. This implies a rapid clearance from the circulation and the fact that NTx in spot urines reflects recent collective osteoclast activity in the skeleton. Such features of a bone resorption marker may be useful for monitoring subtle changes in bone metabolism in individual patients. The present study used a sensitive chemiluminescence method to assess the potential for serum NTx to act as a bone resorption marker. Preliminary studies with a more convenient 96-well plate ELISA format, and use of mAb 1H11, indicate that serum NTx concentrations can also monitor the suppressed bone resorption in postmenopausal women on hormone replacement (31) or alendronate therapy (32). The latter study also showed a diurnal variation in serum NTx concentrations, both in the subjects receiving alendronate therapy and in the controls on placebo. On average, serum NTx peaked in the early morning hours and was lowest in the early evening hours for both groups. A similar diurnal pattern was seen in urine NTx from the same subjects. Further clinical studies are warranted to validate the performance of serum NTx in different states of physiology and disease.


   Acknowledgments
 
We thank Joyce Rafferty for technical support in performing urinary NTx and urinary creatinine measurements, and Brenda Lee for preparing the manuscript. The results were presented in part at the 18th Annual Meeting of the American Society of Bone and Mineral Research, Seattle, WA, September 7–11, 1996.


   Footnotes
 
1 Nonstandard abbreviations: NTx, cross-linked N-telopeptides of type I collagen; HRP, horseradish peroxidase; BCE, bone collagen equivalents.

2 BCE: Bone Collagen Equivalents, units of immunoreactive NTx calibrated in moles of type I collagen in human bone that on digestion in vitro generate the same assay response as immunoreactive NTx (21).


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Delmas PD. Biochemical markers for the assessment of bone turnover. Riggs LB Melton JL, III eds. Osteoporosis: etiology, diagnosis, and management, 2nd ed 1995:319-333 Lippincott–Raven Publishers Philadelphia. .
  2. Kleerekoper M, Edelson GW. Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects. Endocr Pract 1996;2:13-19.
  3. Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 1990;19:1-19. [ISI][Medline] [Order article via Infotrieve]
  4. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 1996;11:337-349. [ISI][Medline] [Order article via Infotrieve]
  5. Taylor AK, Kueken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am 1994;20:589-607. [ISI][Medline] [Order article via Infotrieve]
  6. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas PD, Deftos LJ, Raisz LG. The short-term effects of conjugated estrogen on bone in older women. J Clin Endocrinol Metab 1994;79:366-371. [Abstract]
  7. Uebelhart D, Gineyts E, Chapuy MD, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Mineral 1990;8:87-96. [ISI][Medline] [Order article via Infotrieve]
  8. Robins SP, Black D, Paterson CR, Reid DM, Duncan A, Seibel MJ. Evaluation of hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991;21:310-315. [ISI][Medline] [Order article via Infotrieve]
  9. Eyre DR. New biomarkers of bone resorption [Editorial]. J Clin Endocrinol Metab 1992;74:470A-470C.
  10. Delmas PD, Schlemmer A, Johansen JS, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline cross-links correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res 1991;6:639-644. [ISI][Medline] [Order article via Infotrieve]
  11. Eyre DR, Koob TJ, Van Ness KP. Quantitation of hydroxypyridinium cross-links in collagen by high performance liquid chromatography. Anal Biochem 1984;137:380-388. [ISI][Medline] [Order article via Infotrieve]
  12. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Miner Res 1993;8:643-648. [ISI][Medline] [Order article via Infotrieve]
  13. Gomez B, Jr, Ardakani S, Evans BJ, Merrell LD, Jenkens DK, Kung VT. Monoclonal antibody assay for free urinary pyridinium cross-links. Clin Chem 1996;42:1168-1175. [Abstract/Free Full Text]
  14. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HJK, et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 1994;9:135-142. [ISI][Medline] [Order article via Infotrieve]
  15. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700. [Abstract]
  16. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD. Different effects of bisphosphonates and estrogen therapy on free and peptide-bound bone cross-links excretion. J Bone Min Res 1995;10:641-649. [ISI][Medline] [Order article via Infotrieve]
  17. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of turnover. Calcif Tiss Int 1994;54:26-29. [ISI][Medline] [Order article via Infotrieve]
  18. Kamel S, Brazier M, Rogez JC, Vincent O, Maamer M, Desmet G, Sebert JL. Different responses of free and peptide-bound cross-links to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency. J Clin Endocrinol Metab 1996;81:3717-3721. [Abstract]
  19. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, Wark JD. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996;81:3366-3371. [Abstract]
  20. Eyre DR. The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthop Scand 1995;66(Suppl 266):166-170. [ISI][Medline] [Order article via Infotrieve]
  21. Hanson DA, Weis MAE, Bollen AM, Maslan SH, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type 1 collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258. [ISI][Medline] [Order article via Infotrieve]
  22. Nakane PK, Kawaoi A. Peroxidase-labeled antibody: a new method of conjugation. J Histochem Cytochem 1974;22:1084-1091. [Abstract]
  23. Tietz NW eds. Textbook of clinical chemistry 2nd ed. 1994:1533-1536 WB Saunders Philadelphia. .
  24. Bollen AM, Eyre DR. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides. Bone 1994;15:31-34. [Medline] [Order article via Infotrieve]
  25. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41:1489-1494. [Abstract/Free Full Text]
  26. Blumsohn A, Naylor KE, Assiri AMA, Eastell R. Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 1995;41:1592-1598. [Abstract/Free Full Text]
  27. Sone T, Miyake M, Takeda N, Fukunaga M. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age and sex related changes and reference limits. Bone 1995;17:335-339. [Medline] [Order article via Infotrieve]
  28. Marshall LA, Cain DF, Dmowski WP, Chesnut CH, III. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet Gynecol 1996;87:350-354. [Abstract]
  29. Hanson DA, Eyre DR. Molecular site specificity of pyridinoline and pyrrole crosslinks in type I collagen of human bone. J Biol Chem 1996;271:26508-26516. [Abstract/Free Full Text]
  30. Apone S, Lee M, Eyre D. Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 1997;21:129-136. [Medline] [Order article via Infotrieve]
  31. Prestwood KM, Clemens JD, Fall PM, Pilbeam CC, Raisz LG. The effect of estrogen on serum cross-linked N-telopeptides of type I collagen [Abstract]. J Bone Miner Res 1996;11(Suppl 1):S449.
  32. Greenspan SL, Holland S, Yuan W, Kher U, Clemens JD, Gertz B. Diurnal rhythm of serum NTx: a new marker to assess bone resorption and response to therapy [Abstract]. J Bone Miner Res 1996;11(Suppl 1):S442.



The following articles in journals at HighWire Press have cited this article:


Home page
 Cleveland Clinic Journal of MedicineHome page
F. R. SINGER and D. R. EYRE
Using biochemical markers of bone turnover in clinical practice
Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 739 - 750.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y.-C. Chung, C.-H. Ku, T.-Y. Chao, J.-C. Yu, M. M. Chen, and S.-H. Lee
Tartrate-resistant Acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment.
Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 424 - 428.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Y. Maeno, M. Inaba, S. Okuno, T. Yamakawa, E. Ishimura, and Y. Nishizawa
Serum Concentrations of Cross-Linked N-Telopeptides of Type I Collagen: New Marker for Bone Resorption in Hemodialysis Patients
Clin. Chem., December 1, 2005; 51(12): 2312 - 2317.
[Abstract] [Full Text] [PDF]

Home page
 J Bone Joint Surg BrHome page
L. Savarino, D. Granchi, E. Cenni, N. Baldini, M. Greco, and A. Giunti
Systemic cross-linked N-terminal telopeptide and procollagen I C-terminal extension peptide as markers of bone turnover after total hip arthroplasty
J Bone Joint Surg Br, April 1, 2005; 87-B(4): 571 - 576.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. M. Ali, L. M. Demers, K. Leitzel, H. A. Harvey, D. Clemens, N. Mallinak, L. Engle, V. Chinchilli, L. Costa, C. Brady, et al.
Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis
Ann. Onc., March 1, 2004; 15(3): 455 - 459.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Fohr, C. R. Dunstan, and M. J. Seibel
Markers of Bone Remodeling in Metastatic Bone Disease
J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5059 - 5075.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
L. Martini and R. J Wood
Relative bioavailability of calcium-rich dietary sources in the elderly
Am. J. Clinical Nutrition, December 1, 2002; 76(6): 1345 - 1350.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
K. Jung, M. Lein, K. von Hosslin, B. Brux, D. Schnorr, S. A. Loening, and P. Sinha
Osteoprotegerin in Serum as a Novel Marker of Bone Metastatic Spread in Prostate Cancer
Clin. Chem., November 1, 2001; 47(11): 2061 - 2063.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. M. Brown, R. L. Vessella, P. J. Kostenuik, C. R. Dunstan, P. H. Lange, and E. Corey
Serum Osteoprotegerin Levels Are Increased in Patients with Advanced Prostate Cancer
Clin. Cancer Res., October 1, 2001; 7(10): 2977 - 2983.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
K. O O'Brien, M. Razavi, R. A Henderson, B. Caballero, and K. J Ellis
Bone mineral content in girls perinatally infected with HIV
Am. J. Clinical Nutrition, April 1, 2001; 73(4): 821 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Garnero, O. Borel, and P. D. Delmas
Evaluation of a Fully Automated Serum Assay for C-Terminal Cross-Linking Telopeptide of Type I Collagen in Osteoporosis
Clin. Chem., April 1, 2001; 47(4): 694 - 702.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. J. Janckila, K. Takahashi, S. Z. Sun, and L. T. Yam
Tartrate-resistant Acid Phosphatase Isoform 5b as Serum Marker for Osteoclastic Activity
Clin. Chem., January 1, 2001; 47(1): 74 - 80.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. M. Prestwood, D. L. Thompson, A. M. Kenny, M. J. Seibel, C. C. Pilbeam, and L. G. Raisz
Low Dose Estrogen and Calcium Have an Additive Effect on Bone Resorption in Older Women
J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 179 - 183.
[Abstract] [Full Text]

Home page
 Clin. Chem.Home page
C. Rosenquist, C. Fledelius, S. Christgau, B. J. Pedersen, M. Bonde, P. Qvist, and C. Christiansen
Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen
Clin. Chem., November 1, 1998; 44(11): 2281 - 2289.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (87)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clemens, J. D.
Right arrow Articles by Eyre, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clemens, J. D.
Right arrow Articles by Eyre, D. R.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS